Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNASDAQ:CMRXNASDAQ:QURENYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$10.98+3.6%$8.42$5.51▼$11.73$214.46MN/A47,519 shs131,160 shsCMRXChimerix$8.54$8.53$0.75▼$8.55$801.09M-0.172.44 million shsN/AQUREuniQure$15.50+1.2%$12.39$3.73▼$19.18$849.03M0.11.88 million shs2.38 million shsZYMEZymeworks$11.94-3.9%$11.80$8.21▼$17.70$830.75M1.24597,654 shs423,175 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+3.58%+13.78%+31.18%+40.23%+1,097,999,900.00%CMRXChimerix0.00%0.00%-0.06%+65.18%+775.90%QUREuniQure+1.24%+22.53%+16.63%+19.60%+222.92%ZYMEZymeworks-3.94%+6.13%+1.62%-14.84%+34.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACMRXChimerix0.558 of 5 stars1.00.00.04.10.01.70.6QUREuniQure2.9679 of 5 stars4.52.00.00.01.62.50.6ZYMEZymeworks3.3659 of 5 stars4.50.00.00.03.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.5086.70% UpsideCMRXChimerix 2.00Hold$8.53-0.08% DownsideQUREuniQure 2.91Moderate Buy$37.82143.99% UpsideZYMEZymeworks 2.90Moderate Buy$21.0075.88% UpsideCurrent Analyst Ratings BreakdownLatest ACTU, ZYME, QURE, and CMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/19/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025QUREuniQureGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/12/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/6/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/21/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/1/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$27.00 ➝ $38.003/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/11/2025ZYMEZymeworksLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/ACMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94QUREuniQure$20.20M42.03N/AN/A$4.34 per share3.57ZYMEZymeworks$93.38M8.90N/AN/A$6.63 per share1.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/ACMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%N/AQUREuniQure-$308.48M-$4.39N/AN/AN/A-837.80%-188.82%-32.17%8/7/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%8/7/2025 (Estimated)Latest ACTU, ZYME, QURE, and CMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACTUActuate Therapeutics-$0.26-$0.32-$0.06-$0.32N/AN/A5/9/2025Q1 2025QUREuniQure-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million3/21/2025Q4 2024CMRXChimerix-$0.26-$0.25+$0.01-$0.25$0.31 million$0.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.681.68CMRXChimerixN/A6.336.33QUREuniQure0.926.516.51ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ACMRXChimerix45.42%QUREuniQure78.83%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%CMRXChimerix13.10%QUREuniQure4.74%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.53 millionN/AN/ACMRXChimerix9093.80 million78.15 millionOptionableQUREuniQure50054.78 million46.43 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableACTU, ZYME, QURE, and CMRX HeadlinesRecent News About These CompaniesPoint72 Asset Management L.P. Boosts Stock Position in Zymeworks Inc. (NYSE:ZYME)May 22 at 4:42 AM | marketbeat.comZymeworks (NYSE:ZYME) Stock Price Up 4.2% After Insider Buying ActivityMay 22 at 1:33 AM | americanbankingnews.comZymeworks Inc. Presents Promising Preclinical Data for ZW1528, a Novel Bispecific Antibody Targeting IL-4Rα and IL-33 for Respiratory InflammationMay 21 at 4:05 PM | nasdaq.comZymeworks Inc. (NYSE:ZYME) Stake Lessened by Vestal Point Capital LPMay 21 at 8:14 AM | marketbeat.comTD Securities Initiates Coverage of Zymeworks (ZYME) with Buy RecommendationMay 21 at 6:48 AM | msn.comTD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer TherapyMay 21 at 6:48 AM | msn.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 21 at 6:00 AM | globenewswire.comZymeworks Inc.: Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International ConferenceMay 20 at 10:43 AM | finanznachrichten.dePolar Asset Management Partners Inc. Buys New Holdings in Zymeworks Inc. (NYSE:ZYME)May 20 at 5:29 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 5,919 SharesMay 20 at 5:17 AM | insidertrades.comZymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International ConferenceMay 19 at 4:15 PM | globenewswire.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Prosight Management LPMay 17, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $5.21 Million Position in Zymeworks Inc. (NYSE:ZYME)May 17, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Buys Shares of 22,800 Zymeworks Inc. (NYSE:ZYME)May 15, 2025 | marketbeat.comWall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a BetMay 14, 2025 | zacks.comAnalyst Forecasts For Zymeworks Inc. (NASDAQ:ZYME) Are Surging HigherMay 14, 2025 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Granahan Investment Management LLCMay 12, 2025 | marketbeat.comFarallon Capital Management LLC Sells 31,026 Shares of Zymeworks Inc. (NYSE:ZYME)May 11, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases 123,240 Shares of Zymeworks Inc. (NYSE:ZYME)May 11, 2025 | marketbeat.comZymeworks May 2025 slides: Pipeline expansion amid modest revenue growthMay 10, 2025 | investing.comZymeworks Inc. Reports Financial Results and Highlights Recent Developments, Including Appointment of Dr. Sabeen Mekan and AACR Poster PresentationsMay 10, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongNVIDIA’s NVLink Fusion Ups the Ante for AI InfrastructureBy Thomas Hughes | May 19, 2025View NVIDIA’s NVLink Fusion Ups the Ante for AI InfrastructureRockwell Automation: Tailwinds From Onshoring U.S. ProductionBy Thomas Hughes | May 8, 2025View Rockwell Automation: Tailwinds From Onshoring U.S. ProductionCan Shopify Stock Make a Comeback After an Earnings Sell-Off?By Gabriel Osorio-Mazilli | May 12, 2025View Can Shopify Stock Make a Comeback After an Earnings Sell-Off?ACTU, ZYME, QURE, and CMRX Company DescriptionsActuate Therapeutics NASDAQ:ACTU$10.98 +0.38 (+3.58%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$11.00 +0.02 (+0.17%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Chimerix NASDAQ:CMRX$8.54 0.00 (0.00%) As of 04/21/2025Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.uniQure NASDAQ:QURE$15.50 +0.19 (+1.24%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$15.42 -0.09 (-0.55%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Zymeworks NYSE:ZYME$11.94 -0.49 (-3.94%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$12.51 +0.57 (+4.77%) As of 08:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Palo Alto Networks: Buy The Dip, Long-Term Tailwinds Ahead Lowe’s Stock Uptrend Can Continue for These 2 Reasons CrowdStrike Near Breakout: Is Now the Time to Buy? $30B AI Opportunity: Will It Power Meta’s Next Surge? Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era Rivian Stock Below $20: Charging Up or in the Breakdown Lane? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
